Abstract Details

Title Impact of Immunodepleting Treatment with Alemtuzumab on the Peripheral Treg Compartment in Patients with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 369

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Mirjam Korporal-Kuhnke, MD	Dr. Korporal-Kuhnke has nothing to disclose.
Sven O. Jarius, MD (University of Heidelberg)	Dr. Jarius has nothing to disclose.
Sven G. Meuth (Uniklinik Düsseldorf, Klinik für Neurologie)	Sven G. Meuth has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Sven G. Meuth has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Sven G. Meuth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Almirall. Sven G. Meuth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Sven G. Meuth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Sven G. Meuth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Sven G. Meuth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Sven G. Meuth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche.
Brigitte Wildemann, MD (University Hospital Heidelberg, Department of Neurology)	Dr. Wildemann has nothing to disclose.